Compare iShares MSCI United Kingdom (FTSE) (EWU) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI United Kingdom (FTSE) vs Incyte Corporation — how do they compare? iShares MSCI United Kingdom (FTSE) trades at $48.34, while Incyte Corporation trades at $120.81 (market cap $24.54B). The key difference: iShares MSCI United Kingdom (FTSE) is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals.
| EWU | INCY | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $48.68 | $129.93 |
52-Week Low | $40.90 | $81.61 |
Market Cap | — | $24.54B |
Enterprise Value | — | $20.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWU, the iShares MSCI United Kingdom ETF, trades at $48.33, down 0.33% on the day, with a bullish technical signal driven by moving averages. The ETF tracks UK large-cap equities, with recent institutional activity showing mixed positions. Key support and resistance cluster around $48-$49, while RSI levels indicate neutral momentum. Geopolitical tensions and oil price volatility influence FTSE 100 performance, as highlighted in recent financial news.
The outlook for EWU is cautiously optimistic, supported by technical strength but tempered by macroeconomic risks. Opportunities include exposure to UK market resilience, while risks involve Middle East tensions and inflation concerns. Investors should weigh institutional inflows against broader market volatility for balanced positioning.
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI United Kingdom (FTSE)
EWU is a country-specific ETF that tracks the performance of the United Kingdom equity market. It provides exposure to large and mid-sized UK companies, with significant weightings in financials, energy, and healthcare, including Shell, AstraZeneca, and HSBC.
Read more on EWU →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
